157 related articles for article (PubMed ID: 34152837)
21. Treatment and outcomes of high-risk neuroblastoma in Southeast Asia: a single-institution experience and review of the literature.
Lee AC; Chui CH; Kwok R; Lee KS; Fong CM; Wong WH
Singapore Med J; 2023 May; 64(5):319-325. PubMed ID: 34688228
[TBL] [Abstract][Full Text] [Related]
22. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD
Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472
[TBL] [Abstract][Full Text] [Related]
23. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.
Berthold F; Faldum A; Ernst A; Boos J; Dilloo D; Eggert A; Fischer M; Frühwald M; Henze G; Klingebiel T; Kratz C; Kremens B; Krug B; Leuschner I; Schmidt M; Schmidt R; Schumacher-Kuckelkorn R; von Schweinitz D; Schilling FH; Theissen J; Volland R; Hero B; Simon T
Ann Oncol; 2020 Mar; 31(3):422-429. PubMed ID: 32067684
[TBL] [Abstract][Full Text] [Related]
24. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma.
Balyasny S; Lee SM; Desai AV; Volchenboum SL; Naranjo A; Park JR; London WB; Cohn SL; Applebaum MA
JAMA Netw Open; 2021 Jul; 4(7):e2116248. PubMed ID: 34236408
[TBL] [Abstract][Full Text] [Related]
25. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
26. Evidence for the efficacy of immunotherapy in children with high-risk neuroblastoma.
Szychot E; Peregud-Pogorzelski J; Wawryków P; Brodkiewicz A
Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):1001-1004. PubMed ID: 27708204
[TBL] [Abstract][Full Text] [Related]
27. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.
Holmes K; Pötschger U; Pearson ADJ; Sarnacki S; Cecchetto G; Gomez-Chacon J; Squire R; Freud E; Bysiek A; Matthyssens LE; Metzelder M; Monclair T; Stenman J; Rygl M; Rasmussen L; Joseph JM; Irtan S; Avanzini S; Godzinski J; Björnland K; Elliott M; Luksch R; Castel V; Ash S; Balwierz W; Laureys G; Ruud E; Papadakis V; Malis J; Owens C; Schroeder H; Beck-Popovic M; Trahair T; Forjaz de Lacerda A; Ambros PF; Gaze MN; McHugh K; Valteau-Couanet D; Ladenstein RL;
J Clin Oncol; 2020 Sep; 38(25):2902-2915. PubMed ID: 32639845
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
Zage PE; Kletzel M; Murray K; Marcus R; Castleberry R; Zhang Y; London WB; Kretschmar C;
Pediatr Blood Cancer; 2008 Dec; 51(6):747-53. PubMed ID: 18704922
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
30. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).
Fox E; Mosse' YP; Meany HM; Gurney JG; Khanna G; Jackson HA; Gordon G; Shusterman S; Park JR; Cohn SL; Adamson PC; London WB; Maris JM; Balis FM
Pediatr Blood Cancer; 2014 Jun; 61(6):990-6. PubMed ID: 24347462
[TBL] [Abstract][Full Text] [Related]
31. Dose-intensity analysis and randomized trials.
Heller G; Cheung NK
J Clin Oncol; 1991 Sep; 9(9):1715-6. PubMed ID: 1875228
[No Abstract] [Full Text] [Related]
32. A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis.
Kreitz K; Ernst A; Schmidt R; Simon T; Fischer M; Volland R; Hero B; Berthold F
Cancer Med; 2019 Dec; 8(17):7236-7243. PubMed ID: 31631570
[TBL] [Abstract][Full Text] [Related]
33. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
Matthay KK; Villablanca JG; Seeger RC; Stram DO; Harris RE; Ramsay NK; Swift P; Shimada H; Black CT; Brodeur GM; Gerbing RB; Reynolds CP
N Engl J Med; 1999 Oct; 341(16):1165-73. PubMed ID: 10519894
[TBL] [Abstract][Full Text] [Related]
34. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
35. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.
Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Niethammer D; Berthold F
J Clin Oncol; 2004 Sep; 22(17):3549-57. PubMed ID: 15337804
[TBL] [Abstract][Full Text] [Related]
36. Dinutuximab: A Review in High-Risk Neuroblastoma.
Hoy SM
Target Oncol; 2016 Apr; 11(2):247-53. PubMed ID: 26891967
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro.
Meany HJ; Sackett DL; Maris JM; Ward Y; Krivoshik A; Cohn SL; Steinberg SM; Balis FM; Fox E
Pediatr Blood Cancer; 2010 Jan; 54(1):47-54. PubMed ID: 19731320
[TBL] [Abstract][Full Text] [Related]
38. Retinoid therapy of childhood cancer.
Reynolds CP; Lemons RS
Hematol Oncol Clin North Am; 2001 Oct; 15(5):867-910. PubMed ID: 11765378
[TBL] [Abstract][Full Text] [Related]
39. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Greenwood KL; Foster JH
Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
[TBL] [Abstract][Full Text] [Related]
40. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma.
De Bernardi B; Conte M; Mancini A; Donfrancesco A; Alvisi P; Tomà P; Casale F; Cordero di Montezemolo L; Cornelli PE; Carli M
J Clin Oncol; 1995 Apr; 13(4):884-93. PubMed ID: 7707115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
